CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer

Luigi Racioppi(Duke University), Erik R. Nelson(University of Illinois Urbana-Champaign), Wei Huang(Duke University), Debarati Mukherjee(Duke University), Scott A. Lawrence(Eli Lilly (United States)), William Lento(Duke University), Anna Maria Masci(Duke University), Yiquin Jiao(Duke University), Sung Hee Park(Duke University), Brian York(Baylor College of Medicine), Yaping Liu(Duke University), Amy E. Baek(University of Illinois Urbana-Champaign), David H. Drewry(University of North Carolina at Chapel Hill), William J. Zuercher(University of North Carolina at Chapel Hill), Francesca Romana Bertani(Center for Biomolecular Nanotechnologies), Luca Businaro(Center for Biomolecular Nanotechnologies), Joseph Geradts(City Of Hope National Medical Center), Allison Hall(Duke University), Anthony R. Means(Baylor College of Medicine), Nelson J. Chao(Duke University), Ching‐yi Chang(Duke University), Donald P. McDonnell(Duke University)
Nature Communications
June 4, 2019
Cited by 106Open Access
Full Text

Abstract

Abstract Tumor-associated myeloid cells regulate tumor growth and metastasis, and their accumulation is a negative prognostic factor for breast cancer. Here we find calcium/calmodulin-dependent kinase kinase (CaMKK2) to be highly expressed within intratumoral myeloid cells in mouse models of breast cancer, and demonstrate that its inhibition within myeloid cells suppresses tumor growth by increasing intratumoral accumulation of effector CD8 + T cells and immune-stimulatory myeloid subsets. Tumor-associated macrophages (TAMs) isolated from Camkk2 −/− mice expressed higher levels of chemokines involved in the recruitment of effector T cells compared to WT. Similarly, in vitro generated Camkk2 −/− macrophages recruit more T cells, and have a reduced capability to suppress T cell proliferation, compared to WT. Treatment with CaMKK2 inhibitors blocks tumor growth in a CD8 + T cell-dependent manner, and facilitates a favorable reprogramming of the immune cell microenvironment. These data, credential CaMKK2 as a myeloid-selective checkpoint, the inhibition of which may have utility in the immunotherapy of breast cancer.


Related Papers

No related papers found

Powered by citation graph analysis